Compare BIO-TECHNE Corp (TECH) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Williams Companies Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Williams Companies Inc trades at $72.62 (market cap $87.88B). The key difference: Williams Companies Inc is far larger — about 7.8× BIO-TECHNE Corp's market cap, and Williams Companies Inc pays the higher dividend (2.92%). Which is the better fit depends on your goals.
| TECH | WMB | |
|---|---|---|
Market Cap | $11.24B | $87.88B |
Sector | Health | Energy |
52-Week High | $72.29 | $79.40 |
52-Week Low | $43.31 | $56.51 |
Enterprise Value | $11.32B | $118.51B |
Dividend Yield | 0.44% | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
WMB trades at $70.4, down 1.9% on the day, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year EBITDA guidance to $8.4 billion. Strong profitability is evident with a 25.18% net income margin and 24.02% ROE, though valuation ratios like P/E of 28.05 appear elevated. The recent $5.5 billion acquisition of Momentum Midstream aims to bolster growth in the Haynesville region.
Outlook remains positive with analyst consensus strongly bullish (79% buy ratings) and a $87.14 price target, implying significant upside. Risks include execution of the Momentum integration, volatile energy prices, and high debt levels. Cash flow stability from fee-based contracts supports the dividend, but net cash flow turned negative in 2026 forecasts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
